Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine and transcranial magnetic stimulation for fatigue in multiple sclerosis
2024-516732-97-00Phase 3Authorised
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Clínico San Carlos
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amantadine in multiple sclerosis (MS) (2 arms), sponsored by Fundación para la Investigación Biomédica del Hospital Clínico San Carlos. Primary endpoint: Change in MFIS score. Planned start Nov 2022; status: authorised.
02
Drugs
amantadine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-516732-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516732-97-00.